October 23, 2006 09:49 ET Posts Stock Pick List: Notice of Allowance for New Patent!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL--(Marketwire - October 23, 2006) - names the following stocks to its Stock Pick List: Xechem International Inc. (OTCBB: XKEM), Silicon Laboratories Inc. (NASDAQ: SLAB), Sun Microsystems, Inc. (NASDAQ: SUNW), MetaSolv, Inc. (NASDAQ: MSLV).

Xechem International, Inc. (OTCBB: XKEM) just announced the United States Patent and Trademark Office has issued to Virginia Commonwealth University (VCU) a notice of patent allowance relating to a method of treating Sickle Cell Disease (SCD) with a unique 5-membered heterocyclic anti-sickling agent known as 5-HMF. A notice of allowance is a written notification that a patent application has cleared an internal review and is nearing issuance.

The exclusive, worldwide rights for the production, sales and marketing of 5-HMF for use in the battle against SCD belong to Xechem as part of a collaborative licensing agreement with VCU. In May 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for use of 5-HMF by patients afflicted with SCD. Xechem also announced recently that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on 5-HMF.

Other stocks highlighted include Silicon Laboratories Inc. (NASDAQ: SLAB): Stock Pick List, up 2% on 2 million shares, Sun Microsystems, Inc. (NASDAQ: SUNW): Stock Pick List, down 1% on 1 million shares, MetaSolv, Inc. (NASDAQ: MSLV): Stock Pick List, up 2% on 2 million shares.

"The central bank has left the benchmark short term lending rate at 5.25 percent, unchanged since late June, which marked the end to a two year rate hiking campaign. Before that, the Federal Reserve had raised rates after each of the 17 consecutive meetings over most of the last two years. Despite the rise in interest rates, the Dow has blown past its previous all-time high of 11,722.98 reached in January 2000, and is now hovering near the 12,000 mark." More is available at:'s Daily Stock Updates:, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated thirty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information